Form 8-K - Current report:
SEC Accession No. 0001193125-26-151999
Filing Date
2026-04-13
Accepted
2026-04-13 07:45:15
Documents
11
Period of Report
2026-04-13
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d49895d8k.htm   iXBRL 8-K 53804
  Complete submission text file 0001193125-26-151999.txt   168929

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA allo-20260413.xsd EX-101.SCH 2839
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20260413_lab.xml EX-101.LAB 17233
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20260413_pre.xml EX-101.PRE 10804
14 EXTRACTED XBRL INSTANCE DOCUMENT d49895d8k_htm.xml XML 3518
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 26856477
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)